Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

719 results about "Diagnosis treatment" patented technology

Treatment is generally associated with the medical care provided to the patients. Treatment involves various types of techniques; however the most common ones include application of medicines, surgery, physiotherapy etc. to a patient regarding a disease or its symptoms.

Colon and colon cancer associated polynucleotides and polypeptides

InactiveUS20030109690A1Inhibiting and promoting productionInhibiting and promoting and functionSugar derivativesMicrobiological testing/measurementAntigenCancer antigen
The present invention relates to novel colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon or colon cancer antigens," and the use of such colon or colon cancer antigens for detecting disorders of the colon, particularly the presence of colon cancer and colon cancer metastases. More specifically, isolated colon or colon cancer associated nucleic acid molecules are provided encoding novel colon or colon cancer associated polypeptides. Novel colon or colon cancer polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human colon or colon cancer associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
Owner:HUMAN GENOME SCI INC

Method for diagnosing non-small cell lung cancers

Disclosed are methods for detecting, diagnosing, treating and preventing non-small cell lung cancer using differentially expressed genes. Furthermore, novel human genes, whose expression is elevated in non-small cell lung cancer compared to non-cancerous tissues, are provided. Also disclosed are agents for treating and preventing non-small cell lung cancer as well as methods for identifying further compounds for treating and preventing non-small cell lung cancer.
Owner:ONCOTHERAPY SCI INC

Portable handheld medical diagnostic tool ''Camcorder handle''

InactiveUS20060020176A1Improve diagnosis and therapeutic procedureBronchoscopesLaryngoscopesMedical staffDisease
The portable handheld medical diagnostic tool incorporates camcorder technology and combines multiple diagnostic attachments commonly use by physicians and medical personnel. When attached with various portable instruments, it can be a powerful tool for teaching, diagnostics, therapy of illnesses by virtue of real-time video, audio and other sensory feed on the portable handheld medical diagnostic tool. Video, audio and sensory data can then be transfer to computers or other electronic systems for medical presentation and training or for medical diagnostics. This ability is presently not available.
Owner:BERALL JONATHAN

Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research

ActiveUS20130079424A1Increase relapse riskIncrease riskBiocideMicrobiological testing/measurementCD34Minimal residual disease
Using the methods of the present invention, intermediate (int) levels of aldehyde dehydrogenase (ALDH) activity reliably distinguished leukemic CD34+CD38− cells capable of engrafting immunodeficient mice, from residual normal hematopoietic stem cells that exhibited relatively higher ALDH activity. Minimal residual disease (MRD) detected during complete remission was enriched for the CD34+CD38−ALDHint leukemic cells, and the presence of these cells after therapy highly correlated with subsequent clinical relapse. The methods of the present invention can distinguish normal from leukemic CD34+CD38− cells, and identifies those AML cells associated with relapse. Methods of prediction of relapse of AML patients and methods of treatment are also provided.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products